Toggle navigation
Home
Search
Services
Blog
Contact
About
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude
New York University, New York, NY, United States
Search 38 grants from Jean-Claude Bystryn
Search grants from New York University
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Pain and Hypoxia in Premature Neonates
Better Measures of Bariatric Surgical Quality
A Data Analysis Center for integration of fly and worm modENCODE datasets
Pathogenic Mechanisms of Bacterial Respiratory Pathogens
Improving the Diagnosis of Coronary Artery Disease by Multiple Regression Analysi
Recently added grants:
Administrative Core
Experimental and Analytical Resource Core
Information Dissemination Core
Community and Interpersonal Stress, Alcohol, and Chronic Comorbidities among PLWH
Alcohol and Metabolic Dysregulation in PLWH: Mechanisms Underlying Risk for Comorbidities
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA066669-01A1
Application #
2110107
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-03-01
Project End
1998-02-28
Budget Start
1996-03-01
Budget End
1997-02-28
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
New York University
Department
Dermatology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Related projects
NIH 1997
R21 CA
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude / New York University
NIH 1996
R21 CA
Clinical Trial of an Improved Melanoma Vaccine
Bystryn, Jean-Claude / New York University
Publications
Reynolds, S R; Celis, E; Sette, A et al.
(1998)
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
J Immunol 161:6970-6
Comments
Be the first to comment on Jean-Claude Bystryn's grant